IAC/Interactivecorp vs Roivant Sciences Ltd. Common Shares — how do they compare? IAC/Interactivecorp trades at $40.94 (market cap $3.02B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 8.3× IAC/Interactivecorp's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| PPLI | ROIV | |
|---|---|---|
Market Cap | $3.02B | $25.09B |
Volume | 932,191 | 5,738,571 |
Sector | Media | Health |
52-Week High | $47.62 | $41.81 |
52-Week Low | $31.52 | $16.04 |
Typical Hold Time | 79 Days | 0 Days |
Enterprise Value | $3.51B | $21.36B |
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.93, down 0.87% on the day, with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility, including a significant Q2 2026 beat. Fundamentals reveal mixed performance with negative 2025 net income but improving 2026 projections, while valuation metrics appear attractive with P/E of 6.87 and P/B of 0.59.
The outlook remains positive due to potential MGM acquisition interest and improving 2026 profitability projections, though risks include inconsistent earnings history and negative cash flow trends. Institutional sentiment is bullish with no sell ratings, supporting near-term upside potential if acquisition talks materialize.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →